Cleveland Biolabs (NASDAQ: CBLI) announced the results of a Phase 1 single-blinded, randomized, placebo-controlled, healthy-subject study of CBLB612, an investigational ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE